Lynx Financial
Our approach
Rigour on both sides of the border.
How we prepare, run and negotiate a cross-border transaction, and the framework we use to decide which companies to back.
IProcess
How we run a transaction.
Every engagement follows the same three phases, from understanding the technology to closing on terms every party can stand behind.
IPreparation
Research and positioning
- Understand the technology in depth and map the global competitive landscape.
- Build a tailored investment narrative, adapted for each type of investor.
- Establish a clear, rigorous investment thesis focused on what matters.
IIProcess
Systematic execution
- Identify the best-matched counterparties through structured screening and one-to-one dialogue.
- Support technical, legal and financial due diligence, including reverse diligence.
- Control key milestones and timelines so the deal moves steadily.
IIINegotiation
Realising value
- Build valuation models around the value drivers specific to life sciences.
- Design flexible deal structures that balance risk with long-term incentives.
- Resolve sticking points and align every party around a shared outcome.
IIInvestment criteria
What we look for.
Our six-part screening framework, applied to every company we invest in or take on as a client.
I
Technical innovation
A breakthrough, differentiated medical technology or product.
II
Market competitiveness
Clear positioning and competitiveness in its target markets.
III
IP moat
A broad, deep patent position and durable technical barriers.
IV
Team
Strong execution and the capacity to keep innovating under pressure.
V
Global outlook
A strategy that turns local innovation into global value.
VI
Product maturity
Proven progress from laboratory concept to commercial product.